Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Director | September 27, 2021 | September 29, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
C4 Therapeutics, Inc.
Report date September 27, 2021 · Filed September 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 31,681 |
Reported balance
After 2021-09-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-09-27 · Sale · Disposed 539 · Balance 31,681 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| Common StockSEC Table I · non-derivative | IndirectBy ERP Business Holdings, LP | 503,126 |
Reported balance
After 2021-09-27 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-09-27 · Sale · Disposed 1,311 · Balance 503,126 F3: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 27, 2021 Filed Sep 29, 2021 22:33 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 1,311 | $50.04 | $65,604.01 |
DisclosureSEC source: 0001209191-21-058111 · doc4.xml · nonDerivative · entry 2 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By ERP Business Holdings, LP Disclosed balance after: 503,126 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · ownership.nature: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 22:33 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 539 | $50.04 | $26,969.03 |
DisclosureSEC source: 0001209191-21-058111 · doc4.xml · nonDerivative · entry 1 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 31,681 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 24, 2021 Filed Sep 24, 2021 20:51 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 2,115 | $50.10 | $105,963.62 |
DisclosureSEC source: 0001209191-21-057633 · doc4.xml · nonDerivative · entry 8 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By ERP Business Holdings, LP Disclosed balance after: 504,437 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · ownership.nature: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| September 24, 2021 Filed Sep 24, 2021 20:51 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 900 | $50.11 | $45,101.25 |
DisclosureSEC source: 0001209191-21-057633 · doc4.xml · nonDerivative · entry 7 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 32,220 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.28. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 23, 2021 Filed Sep 24, 2021 20:51 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 1,007 | $51.08 | $51,434.74 |
DisclosureSEC source: 0001209191-21-057633 · doc4.xml · nonDerivative · entry 6 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By ERP Business Holdings, LP Disclosed balance after: 506,552 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.00 to $51.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · ownership.nature: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| September 23, 2021 Filed Sep 24, 2021 20:51 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 11,801 | $50.35 | $594,193.33 |
DisclosureSEC source: 0001209191-21-057633 · doc4.xml · nonDerivative · entry 5 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By ERP Business Holdings, LP Disclosed balance after: 507,559 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.99. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · ownership.nature: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| September 23, 2021 Filed Sep 24, 2021 20:51 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 446 | $51.09 | $22,784.40 |
DisclosureSEC source: 0001209191-21-057633 · doc4.xml · nonDerivative · entry 4 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 33,120 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.04 to $51.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 23, 2021 Filed Sep 24, 2021 20:51 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 5,926 | $50.35 | $298,359.29 |
DisclosureSEC source: 0001209191-21-057633 · doc4.xml · nonDerivative · entry 3 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 33,566 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.99. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 20:51 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 7,004 | $50.09 | $350,860.48 |
DisclosureSEC source: 0001209191-21-057633 · doc4.xml · nonDerivative · entry 2 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By ERP Business Holdings, LP Disclosed balance after: 519,360 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · ownership.nature: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 20:51 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 3,544 | $50.10 | $177,554.40 |
DisclosureSEC source: 0001209191-21-057633 · doc4.xml · nonDerivative · entry 1 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 39,492 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.31. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 21, 2021 Filed Sep 21, 2021 23:26 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 5,333 | $50.14 | $267,409.95 |
DisclosureSEC source: 0001209191-21-057118 · doc4.xml · nonDerivative · entry 4 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By ERP Business Holdings, LP Disclosed balance after: 526,364 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 · ownership.nature: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| September 21, 2021 Filed Sep 21, 2021 23:26 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 4,988 | $50.13 | $250,051.43 |
DisclosureSEC source: 0001209191-21-057118 · doc4.xml · nonDerivative · entry 3 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 43,036 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 23:26 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 5,688 | $50.05 | $284,686.68 |
DisclosureSEC source: 0001209191-21-057118 · doc4.xml · nonDerivative · entry 2 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By ERP Business Holdings, LP Disclosed balance after: 531,697 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 · ownership.nature: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 23:26 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 5,152 | $50.04 | $257,808.14 |
DisclosureSEC source: 0001209191-21-057118 · doc4.xml · nonDerivative · entry 1 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 48,024 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 16, 2021 Filed Sep 16, 2021 23:31 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 346 | $50.01 | $17,305.05 |
DisclosureSEC source: 0001209191-21-056482 · doc4.xml · nonDerivative · entry 7 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By ERP Business Holdings, LP Disclosed balance after: 510,385 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.045. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 · ownership.nature: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| September 16, 2021 Filed Sep 16, 2021 23:31 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 25,807 | $48.62 | $1,254,676.98 |
DisclosureSEC source: 0001209191-21-056482 · doc4.xml · nonDerivative · entry 6 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By ERP Business Holdings, LP Disclosed balance after: 510,731 F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.50 to $49.165. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 · ownership.nature: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| September 16, 2021 Filed Sep 16, 2021 23:31 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 346 | $50.01 | $17,302.94 |
DisclosureSEC source: 0001209191-21-056482 · doc4.xml · nonDerivative · entry 5 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 53,176 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 23:31 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 24,193 | $48.97 | $1,184,690.08 |
DisclosureSEC source: 0001209191-21-056482 · doc4.xml · nonDerivative · entry 4 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By ERP Business Holdings, LP Disclosed balance after: 563,538 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.80 to $49.32. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 · ownership.nature: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 23:31 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 30,000 | $48.71 | $1,461,204.00 |
DisclosureSEC source: 0001209191-21-056482 · doc4.xml · nonDerivative · entry 3 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 53,522 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.25 to $49.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 23:31 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 492 | $50.03 | $24,613.58 |
DisclosureSEC source: 0001209191-21-056482 · doc4.xml · nonDerivative · entry 2 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By ERP Business Holdings, LP Disclosed balance after: 587,731 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.145. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 · ownership.nature: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 23:31 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 492 | $50.01 | $24,603.39 |
DisclosureSEC source: 0001209191-21-056482 · doc4.xml · nonDerivative · entry 1 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 83,522 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.145. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 20:10 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 3,330 | $50.07 | $166,743.42 |
DisclosureSEC source: 0001209191-21-055886 · doc4.xml · nonDerivative · entry 4 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By ERP Business Holdings, LP Disclosed balance after: 588,223 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.54. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 · ownership.nature: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 20:10 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 3,330 | $50.07 | $166,730.44 |
DisclosureSEC source: 0001209191-21-055886 · doc4.xml · nonDerivative · entry 3 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 84,014 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.54. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:10 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 1,320 | $50.01 | $66,009.90 |
DisclosureSEC source: 0001209191-21-055886 · doc4.xml · nonDerivative · entry 2 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By ERP Business Holdings, LP Disclosed balance after: 591,553 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 · ownership.nature: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:10 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 1,230 | $50.00 | $61,500.98 |
DisclosureSEC source: 0001209191-21-055886 · doc4.xml · nonDerivative · entry 1 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 87,344 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 23:35 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 14,407 | $45.16 | $650,586.98 |
DisclosureSEC source: 0001209191-21-050057 · doc4.xml · nonDerivative · entry 1 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 88,574 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 02, 2021 Filed Aug 2, 2021 22:47 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 4,257 | $45.01 | $191,606.29 |
DisclosureSEC source: 0001209191-21-049118 · doc4.xml · nonDerivative · entry 2 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 102,981 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 22:47 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 11,336 | $45.00 | $510,167.61 |
DisclosureSEC source: 0001209191-21-049118 · doc4.xml · nonDerivative · entry 1 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 107,238 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:16 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $37.66 | $0.00 |
DisclosureSEC source: 0001209191-21-041426 · doc4.xml · derivative · entry 1 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2022 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 01:23 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionSeries A Preferred Stock · Derivative | 5,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027688 · doc4.xml · derivative · entry 4 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By ERP Business Holdings, LP Disclosed balance after: 0 Underlying: Common Stock · 592,873 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F2 · ownership.nature: Shares held by ERP Business Holdings, LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 01:23 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionSeries A Preferred Stock · Derivative | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027688 · doc4.xml · derivative · entry 3 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 118,574 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 01:23 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionCommon Stock | 592,873 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-027688 · doc4.xml · nonDerivative · entry 2 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By ERP Business Holdings, LP Disclosed balance after: 592,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F2 · ownership.nature: Shares held by ERP Business Holdings, LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 01:23 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionCommon Stock | 118,574 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-027688 · doc4.xml · nonDerivative · entry 1 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 118,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. Read SEC document |
| October 01, 2020 Filed Oct 6, 2020 01:00 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 17,786 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027446 · doc4.xml · derivative · entry 1 Prokupets Elena · CIK 0001824823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,786 Underlying: Common Stock · 17,786 shares Expires 2030-09-30 F1 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) October 1, 2021, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.